Τρίτη, 26 Ιουλίου 2016
Σάββατο, 2 Ιουλίου 2016
FiercePharma | Eric Palmer
The European Medicines Agency, the drug regulator for Europe, is headquartered in London. The problem is that the U.K. voted Thursday to leave the European Union, meaning the EMA will now have to leave and find a new home. It is one of the countless concerns that affect the pharma industry with Britain’s historic vote to give up on European unity.
Over the warnings of business leaders in pharma and all other industries, U.K. voters by a 52% to 48% margin opted to quit the E.U. While the vote is not even legally binding, U.K Prime Minister David Cameron has said he would do as voters decided. He has pledged to resign.
The financial reaction was immediate and messy. The London FTSE 100 index sank by 8%, the biggest fall in more than three decades, before recovering slightly to trade down 5%. The broader FTSE 250 index has dropped 7.5%. The pound hit its lowest level against the dollar in 31 years touching $1.3236, as investors tried to puzzle through what the vote means for businesses.
Τετάρτη, 29 Ιουνίου 2016
Throw another ad spending title on pharma’s growing pile.
Advertising Age’s annual ranking of the 200 leading national advertisers in the U.S. found that pharma industry spending rose more than any other category, increasing overall by 15.6% last year.
And it was way ahead of the rest, too. Travel came in second at 10.1%, while the apparel industry came in third with total ad spending rising by 6.9%. Spending across all categories increased almost unanimously; only the food category dropped, down 2.7%.
And on Ad Age’s top 10 list of the fastest-growing spenders for the year, half were pharma companies. Novo Nordisk ranked highest of those at No. 4 with a 195% spending increase year-over-year to reach $261 million. Valeant Pharmaceuticals was No. 5 with an 88% increase to $441 million, followed by GlaxoSmithKline at No. 6 with a 56% increase to $948 million in ad spending.